The report "HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, kits, software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region - Global Forecast to 2028", is expected to reach USD 1.1 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.3%. Factors such as the increasing transplants volume worldwide, rising number of transplant diagnostic centers, technological advancements, government initiatives to boost HLA typing services , rising public -private investments boost research in HLA genotyping, and increased focus of players to enhance their manufacturing distribution capabilities across emerging countries are likely to support the growth of HLA typing for transplant market during the forecast period.
Browse 159 market data Tables and 42 Figures spread through 212 Pages and in-depth TOC on "HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, kits, software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/transplant-diagnostics-market-96374742.html
Based on the product and service, the reagents consumables segment held the largest share of the market in 2022.
Based on the product service, the HLA typing for the transplants market is segmented into software services, reagents consumables, instruments. The reagents consumables segment held the largest share of the global HLA typing for the transplants market in 2022. Growing need for reliable, faster identification of HLA alleles during transplantation is likely to boost the growth of this segment.
Based on technology, the molecular assays segment held the largest share of the market in 2022.
Based on technology, the HLA typing for the transplants market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technology segment captured the largest market share of HLA typing for transplant market by technology. This is attributed the strong adoption of molecular based technology such as NGS and PCR systems for HLA typing among transplant centers, and hospitals and technological and the ability to provide higher resolution HLA typing over serological methods.
Based on the end user , the independent reference laboratories segment accounted for the largest share of this market in 2022.
Based on the end user , the HLA typing for the transplants market is categorized into independent reference laboratories, hospitals transplant centers , and research laboratories academic institutes. independent reference laboratories accounted for the largest share of the HLA typing for the transplants market in 2022 owing to the capacity of reference laboratories to process large and volume of sample, presence of expertise performing complex HLA tests and interpreting results offering offering high quality HLA typing services.
North America accounted for the largest share of the HLA typing for transplants market in 2022.
North America accounted for the largest share of the HLA typing for the transplants market in 2022, followed by Europe. The Asia Pacific is estimated to be the fastest-growing regional market for HLA typing for transplants market during the forecast period.
The dominance of North America in HLA typing for transplant market is attributed to the rapid surge in the organ transplantation procedures, strong foothold of players offering transplant diagnostic products (including HLA typing), and rising research collaborations to identify the novel HLA genes and their role in organ transplantation.
Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific (US) Illumina, Inc. (US), QIAGEN (Germany), CareDx (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US), Luminex Corporation (US), TBG Diagnostics Limited. (Australia ) FUJIREBIO (Japan),Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
Comments
0 comment